Én gang daglig regimet med abacavir støttes af et 48 ugers multi- center, dobbelblindt, kontrolleret studie (CNA30021) af 770 HIV- inficerede, terapinaive voksne.
The once daily regimen of abacavir is supported by a 48 weeks multi-centre, double-blind, controlled study (CNA30021) of 770 HIV-infected, therapy-naïve adults.